Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion type Assertion NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_head.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion wasGeneratedBy ECO_0000203 NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_provenance.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion wasDerivedFrom befree-20150227 NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_provenance.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion SIO_000772 23656699 NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_provenance.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion evidence source_evidence_literature NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_provenance.
- NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_assertion description "[These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235463.RAB1HWFVHvuRMzfvIK-JwdzDAx6MfIXBl0nVCQSfoR3yI130_provenance.